Bloomberg -- Dr. Reddy’s Laboratories Ltd. may be the biggest beneficiary among Indian generic-drug makers as $157 billion of medicines including Eli Lilly & Co.’s Zyprexa lose patent protection within five years, HDFC Securities Ltd. said.
Bloomberg -- Dr. Reddy’s Laboratories Ltd. may be the biggest beneficiary among Indian generic-drug makers as $157 billion of medicines including Eli Lilly & Co.’s Zyprexa lose patent protection within five years, HDFC Securities Ltd. said.
